RDGL Документы SEC - Vivos Inc.- Годовой отчет, доверенное заявление, проспект эмиссии

Основная статистика

CIK

1449349

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Vivos Inc.

SEC Filings (Chronological Order)

На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.

August 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 000-53497 VIVOS INC
May 9, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 000-53497 VIVOS INC
March 24, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-53497 VIVOS INC (Exact name of re
February 10, 2025	8-K	Unregistered Sales of Equity Securities, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 VIVOS INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File Number) (I
February 10, 2025	EX-99.1	Vivos Inc. Reports Encouraging Human Clinical Trial Results and Announces Expansion Plans Exhibit 99.1 Vivos Inc. Reports Encouraging Human Clinical Trial Results and Announces Expansion Plans (Richland, WA – February 4, 2025) – Vivos Inc. (OTCQB: RDGL) is pleased to report that the first five patients demonstrated the safety of RadioGel Precision Radionuclide TherapyTM by satisfying the criteria in the Clinical Study Plan, including confirmation via PET imaging that the Y-90 remained
February 10, 2025	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2025 VIVOS INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File Number) (I
November 18, 2024	253G2	VIVOS INC. Up to 60,000,000 Shares of Common Stock, par value $0.001 per share at an offering price of $0.12 per Share ($7,200,000) 253G2 1 form253g2.htm Filed Pursuant to Rule 253(g)(2) File No. 024-12456 VIVOS INC. Up to 60,000,000 Shares of Common Stock, par value $0.001 per share at an offering price of $0.12 per Share ($7,200,000) This Post-Qualification Offering Circular Supplement No. 1 (the “Supplement”) supplements the offering circular of Vivos Inc. (the “Company”), dated as qualified on July 16, 2024, and as may be
November 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: SEPTEMBER 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 000-53497 VIVOS
August 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: JUNE 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 000-53497 VIVOS INC
July 15, 2024	ADD EXHB	CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM Exhibit 11.1 CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM We consent to the inclusion in this Amendment #1 to the Registration Statement to Form 1-A, of our audit report dated March 18, 2024, with respect to the balance sheets of Vivos Inc. as of December 31, 2023 and 2022, and the related statements of operations, changes in stockholders’ equity, and cash flows for each of the years in the t
July 15, 2024	PART II AND III	PRELIMINARY OFFERING CIRCULAR DATED JULY 15, 2024 PRELIMINARY OFFERING CIRCULAR DATED JULY 15, 2024 AN OFFERING STATEMENT PURSUANT TO REGULATION A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
July 15, 2024	ADD EXHB	VIVOS INC. SUBSCRIPTION AGREEMENT NOTICE TO INVESTORS Exhibit 4.1 VIVOS INC. SUBSCRIPTION AGREEMENT NOTICE TO INVESTORS THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN IND
July 15, 2024	ADD EXHB	OPINION AND CONSENT OF DISCLOSURE LAW GROUP Exhibit 12.1 OPINION AND CONSENT OF DISCLOSURE LAW GROUP July 12, 2024 Vivos Inc. 719 Jadwin Avenue Richland, Washington 99352 Re: Offering Statement on Form 1-A for Vivos Inc. Ladies and Gentlemen: We have acted as counsel to Vivos Inc., a Delaware corporation (the “Company”), in connection with the Offering Statement on Form 1-A (the “Offering Statement”) filed by the Company with the Securities
July 15, 2024	CORRESP	VIVOS INC. VIVOS INC. July 15, 2024 Mr. Benjamin Richie Division of Corporation Finance Office of Industrial Applications and Services Securities and Exchange Commission Washington DC 20549 Re: Vivos Inc. Offering Statement on Form 1-A Amendment No. 1 File No. 024-12456 Dear Mr. Richie: On behalf of Vivos Inc. I hereby request qualification of the above-referenced offering statement at 4:00 PM Eastern time o
July 1, 2024	EX-99.1	Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials Exhibit 99.1 Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials (Richland WA June 28, 2024) Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”). The filing was an amendment, addressing the FDA comments to our previous application (Q211938/S001). Today’s IDE submission marks our first filing with the F
July 1, 2024	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 VIVOS INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File Number) (IRS
June 28, 2024	PART II AND III	PRELIMINARY OFFERING CIRCULAR DATED JUNE 28, 2024 PRELIMINARY OFFERING CIRCULAR DATED JUNE 28, 2024 AN OFFERING STATEMENT PURSUANT TO REGULATION A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
May 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: March 31, 2024 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 VIVOS INC (Exac
March 25, 2024	EX-10.12	Amended and Restated Employment Agreement between Vivos Inc. and Michael Korenko. Dated December 19, 2023, with a deemed effective date of January 1, 2024 Exhibit 10.12 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this “Agreement”) is made and entered into as of this 19th day of December 2023 (the “Execution Date”), with a deemed effective date of January 1, 2024 (the “Effective Date”) by and between Vivos Inc., a company formed under the laws of the State of Delaware, with its principal place of business
March 25, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 VIVOS INC. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 VIVOS INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File Number) (
March 18, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-53497 VIVOS INC (Exact name of re
March 18, 2024	EX-10.12	Amended and Restated Employment Agreement between Vivos Inc. and Michael Korenko. Dated December 19, 2023, with a deemed effective date of January 1, 2024 Exhibit 10.12 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this “Agreement”) is made and entered into as of this 19th day of December 2023 (the “Execution Date”), with a deemed effective date of January 1, 2024 (the “Effective Date”) by and between Vivos Inc.., a company formed under the laws of the State of Delaware, with its principal place of busines
December 27, 2023	EX-10.1	Form of Series C Warrant Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on December 27, 2023). Exhibit 10.1 Warrant PURCHASE AGREEMENT This Warrant Purchase Agreement (this “Agreement”) is dated as of December , 2023, between Vivos, Inc., a Delaware corporation (the “Company”), and the purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser”) WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section
December 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 VIVOS INC. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 VIVOS INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File Number) (
December 27, 2023	EX-4.1	Form of Series C Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on December 27, 2023). Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
December 27, 2023	EX-10.2	Form of Warrant Exchange Agreement (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on December 27, 2023. Exhibit 10.2 WARRANT EXCHANGE AGREEMENT This Warrant Exchange Agreement (this “Agreement”), dated as of December 21, 2023 (the “Effective Date”), is entered into by and between Vivos Inc, a Delaware corporation (the “Company”), and (the “Warrant Holder”). recitals WHEREAS, the Warrant Holder is the beneficial holder of a Series B warrant, dated June 30, 2022, to purchase shares (the “Warrant”) of
December 22, 2023	253G2	VIVOS INC. Up to 50,000,000 Shares of Common Stock, par value $0.001 per share, at an offering price of $0.064 per Share ($3,200,000) Filed Pursuant to Rule 253(g)(2) File No. 024-11627 VIVOS INC. Up to 50,000,000 Shares of Common Stock, par value $0.001 per share, at an offering price of $0.064 per Share ($3,200,000) This Post-Qualification Offering Circular Supplement No. 1 (the “Supplement”) supplements the offering circular of Vivos Inc. (the “Company”), dated November 27, 2023, as qualified on December 6, 2023, and as may b
December 5, 2023	CORRESP	VIVOS INC. VIVOS INC. Mr. Juan Grana and Ms. Katherine Bagley Division of Corporation Finance Office of Industrial Applications and Services Securities and Exchange Commission Washington DC 20549 December 5, 2023 Re: Vivos Inc. Offering Statement on Form 1-A Post-Qualification Amendment No. 4 File No. 024-11627 Dear Mr. Grana and Ms. Bagley: On behalf of Vivos Inc. I hereby request qualification of the above
November 27, 2023	ADD EXHB	OPINION AND CONSENT OF DISCLOSURE LAW GROUP Exhibit 12.1 OPINION AND CONSENT OF DISCLOSURE LAW GROUP November 27, 2023 Vivos Inc. 719 Jadwin Avenue Richland, Washington 99352 Re: Offering Statement on Form 1-A for Vivos Inc. Ladies and Gentlemen: We have acted as counsel to Vivos Inc., a Delaware corporation (the “Company”), in connection with the Offering Statement on Form 1-A (the “Offering Statement”) filed by the Company with the Securi
November 27, 2023	PART II AND III	PRELIMINARY OFFERING CIRCULAR DATED NOVEMBER 27, 2023 AN OFFERING STATEMENT PURSUANT TO REGULATION A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. INFORMATION CONTAINED IN THIS PRELIMINARY OFFERING CIRCULAR Post-Qualification Amendment No. 4 File No. 024-11627 This Post-Qualification Amendment No. 4 amends the Offering Statement of Vivos Inc. (the “Company”), originally filed with the Securities and Exchange Commission (the “SEC”) on September 1, 2021 (File number 024-11627), as supplemented, and as amended on October 4, 2022, October 10, 2023 and November 6, 2023 to add, update and/or replace the in
November 27, 2023	ADD EXHB	CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM Exhibit 11.1 CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM We consent to the inclusion in the Registration Statement to Form 1-A, Amendment #4 (File No. 024-11627) of our audit report dated March 1, 2023, with respect to the balance sheets of Vivos Inc. as of December 31, 2022 and 2021, and the related statements of operations, changes in stockholders’ equity, and cash flows for each of the ye
November 27, 2023	CORRESP	November 27, 2023 November 27, 2023 VIA EDGAR Mr. Juan Grana and Ms. Katherine Bagley United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: VIVOS INC Post-Qualification Amendment No. 3 to Offering Statement on Form 1-A Filed November 3, 2023 File No. 024-11627 Ladies and Gentlemen: This letter is submitted on behalf of Vivos Inc. (the “Company
November 6, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: September 30, 2023 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 VIVOS INC (
November 3, 2023	ADD EXHB	CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM Exhibit 11.1 CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM We consent to the inclusion in the Registration Statement to Form 1-A, Amendment #3 (File No. 024-11627) of our audit report dated March 1, 2023, with respect to the balance sheets of Vivos Inc. as of December 31, 2022 and 2021, and the related statements of operations, changes in stockholders’ equity, and cash flows for each of the ye
November 3, 2023	PART II AND III	PRELIMINARY OFFERING CIRCULAR DATED November 3, 2023 AN OFFERING STATEMENT PURSUANT TO REGULATION A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. INFORMATION CONTAINED IN THIS PRELIMINARY OFFERING CIRCULAR I Post-Qualification Amendment No. 3 File No. 024-11627 This Post-Qualification Amendment No. 3 amends the Offering Statement of Vivos Inc. (the “Company”), originally filed with the Securities and Exchange Commission (the “SEC”) on September 1, 2021 (File number 024-11627), as supplemented, and as amended on October 4, 2022 and October 10, 2023, to add, update and/or replace the information contain
November 3, 2023	ADD EXHB	OPINION AND CONSENT OF DISCLOSURE LAW GROUP Exhibit 12.1 OPINION AND CONSENT OF DISCLOSURE LAW GROUP November 3, 2023 Vivos Inc. 719 Jadwin Avenue Richland, Washington 99352 Re: Offering Statement on Form 1-A for Vivos Inc. Ladies and Gentlemen: We have acted as counsel to Vivos Inc., a Delaware corporation (the “Company”), in connection with the Offering Statement on Form 1-A (the “Offering Statement”) filed by the Company with the Securit
November 3, 2023	CORRESP	November 3, 2023 November 3, 2023 VIA EDGAR Mr. Juan Grana and Ms. Katherine Bagley United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: VIVOS INC Post-Qualification Amendment No. 2 to Offering Statement on Form 1-A Filed October 10, 2023 File No. 024-11627 Ladies and Gentlemen: This letter is submitted on behalf of Vivos Inc. (the “Company”
October 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 VIVOS INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 VIVOS INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File Number) (I
October 11, 2023	EX-99.1	Quarterly Progress Report Exhibit 99.1 Quarterly Progress Report Intellectual Property Intellectual property remains a priority. Patents ● The provisional patent on the chiller and related equipment expires on 12/30/23 so we authorized Indiano Law Group to file for a utility patent based on the chiller, but including the combined shipping pig/vial holder and syringe shield. Chances are good that the patent office will forc
October 10, 2023	ADD EXHB	OPINION AND CONSENT OF DISCLOSURE LAW GROUP Exhibit 12.1 OPINION AND CONSENT OF DISCLOSURE LAW GROUP October 10, 2023 Vivos Inc. 719 Jadwin Avenue Richland, Washington 99352 Re: Offering Statement on Form 1-A for Vivos Inc. Ladies and Gentlemen: We have acted as counsel to Vivos Inc., a Delaware corporation (the “Company”), in connection with the Offering Statement on Form 1-A (the “Offering Statement”) filed by the Company with the Securit
October 10, 2023	ADD EXHB	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 11.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the inclusion in the Registration Statement to Form 1-A, Amendment 2 (File No. 024-11627) of our audit report dated March 1, 2023, with respect to the balance sheets of Vivos Inc. as of December 31, 2022 and 2021, and the related statements of operations, changes in stockholders’ equity, and cash flows for each of
October 10, 2023	PART II AND III	PRELIMINARY OFFERING CIRCULAR DATED OCTOBER 10, 2023 AN OFFERING STATEMENT PURSUANT TO REGULATION A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. INFORMATION CONTAINED IN THIS PRELIMINARY OFFERING CIRCULAR I Post-Qualification Amendment No. 2 File No. 024-11627 This Post-Qualification Amendment No. 2 amends the Offering Statement of Vivos Inc. (the “Company”), originally filed with the Securities and Exchange Commission (the “SEC”) on September 1, 2021 (File number 024-11627), as supplemented, and as amended on October 4, 2022 to add, update and/or replace the information contained in the Offering Sta
August 4, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: June 30, 2023 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 VIVOS INC (Exact
May 4, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: March 31, 2023 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 VIVOS INC (Exac
May 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 VIVOS INC. (Exact Nam UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 VIVOS INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Em
March 1, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-53497 VIVOS INC (Exact name of registra
October 19, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: September 30, 2022 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 VIVOS INC (
October 13, 2022	CORRESP	VIVOS INC. VIVOS INC. Jordan Nimitz Division of Corporation Finance Office of Industrial Applications and Services Securities and Exchange Commission Washington DC 20549 October 13, 2022 Re: Vivos Inc. Offering Statement on Form 1-A Post-Qualification Amendment No. 1 File No. 024-11627 Dear Ms. Nimitz: On behalf of Vivos Inc. I hereby request qualification of the above-referenced offering statement at 3:00 P
October 3, 2022	ADD EXHB	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 11.1 802 N Washington St Spokane, WA 99201 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the inclusion in this Post-Qualification Amendment No 1. to the Offering Statement on From 1-A of our audit report dated March 7, 2022, with respect to the balance sheets of Vivos, Inc. as of December 31, 2021 and December 31, 2020, and the related statements of operations, cha
October 3, 2022	PART II AND III	PRELIMINARY OFFERING CIRCULAR DATED OCTOBER 3, 2022 AN OFFERING STATEMENT PURSUANT TO REGULATION A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. INFORMATION CONTAINED IN THIS PRELIMINARY OFFERING CIRCULAR IS Post-Qualification Amendment No. 1 File No. 024-11627 This Post-Qualification Amendment No. 1 amends the Offering Statement of Vivos Inc. (the ?Company?), originally filed with the Securities and Exchange Commission (the ?SEC?) on September 1, 2021 (File number 024-11627), as supplemented, to add, update and/or replace the information contained in the Offering Statement. PRELIMINARY OFFERING CIRCU
October 3, 2022	ADD EXHB	OPINION AND CONSENT OF DISCLOSURE LAW GROUP ADD EXHB 4 ex12-1.htm Exhibit 12.1 OPINION AND CONSENT OF DISCLOSURE LAW GROUP September 29, 2022 Vivos Inc. 719 Jadwin Avenue Richland, Washington 99352 Re: Offering Statement on Form 1-A for Vivos Inc. Ladies and Gentlemen: We have acted as counsel to Vivos Inc., a Delaware corporation (the “Company”), in connection with the Offering Statement on Form 1-A (the “Offering Statement”) filed by the
July 25, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: June 30, 2022 OR ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 VIVOS INC (Exact
July 11, 2022	EX-10.2	Form of Series B Warrant (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on July 11, 2022). Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
July 11, 2022	EX-10.1	Form of Series A Warrant (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on July 11, 2022). EX-10.1 2 ex10-1.htm Exhibit 10.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT T
July 11, 2022	8-K	Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2022 VIVOS INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File Number) (IRS E
July 6, 2022	253G2	VIVOS INC. Up to 50,000,000 Shares of Common Stock, par value $0.001 per share at an offering price of $0.08 per Share ($4,000,000) Filed Pursuant to Rule 253(g)(2) File No. 024-11627 VIVOS INC. Up to 50,000,000 Shares of Common Stock, par value $0.001 per share at an offering price of $0.08 per Share ($4,000,000) This Post-Qualification Offering Circular Supplement No. 1 (the ?Supplement?) supplements the offering circular of Vivos Inc. (the ?Company?), dated September 1, 2021, as qualified on September 15, 2021, and as may b
May 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: March 31, 2022 OR ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 VIVOS INC (Exac
March 7, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-53497 VIVOS INC (Exact name of registra
January 27, 2022	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2022 VIVOS INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File Number) (I
January 27, 2022	EX-99.1	Vivos Inc. Provides 2021 Recap and Outlines 2022 Objectives Exhibit 99.1 Vivos Inc. Provides 2021 Recap and Outlines 2022 Objectives (Richland WA January 24, 2022) Vivos Inc. (OTCQB: RDGL), provides 2021 recap and outlines future objectives. Vivos? CEO, Dr. Mike Korenko stated, ?as we begin 2022, we wanted to review our progress during the past year and provide insights on our thinking for 2022 and beyond.? Highlights for 2021 include the following: ? ISOP
October 25, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: September 30, 2021 OR ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 VIVOS INC (
September 13, 2021	CORRESP	VIVOS INC. VIVOS INC. Laura Crotty Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission Washington DC 20549 September 13, 2021 Re: Vivos Inc. Offering Statement on Form 1-A File No. 024-11627 Dear Ms. Crotty: On behalf of Vivos Inc. I hereby request qualification of the above-referenced offering statement at 4:00 PM Eastern time on September 15, 2021, or as soon thereaft
September 1, 2021	EX1A-11 CONSENT	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 11.1 802 N Washington St Spokane, WA 99201 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the inclusion in this Offering Statement on Form 1-A of our audit report dated March 24, 2021, with respect to the balance sheets of Vivos, Inc. as of December 31, 2020 and December 31, 2019, and the related statements of operations, changes in stockholders? equity, and cash fl
September 1, 2021	PART II AND III	PRELIMINARY OFFERING CIRCULAR DATED SEPTEMBER 1, 2021 AN OFFERING STATEMENT PURSUANT TO REGULATION A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. INFORMATION CONTAINED IN THIS PRELIMINARY OFFERING CIRCULAR PRELIMINARY OFFERING CIRCULAR DATED SEPTEMBER 1, 2021 AN OFFERING STATEMENT PURSUANT TO REGULATION A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
September 1, 2021	EX1A-12 OPN CNSL	OPINION AND CONSENT OF DISCLOSURE LAW GROUP EX1A-12 OPN CNSL 4 ex12-1.htm Exhibit 12.1 OPINION AND CONSENT OF DISCLOSURE LAW GROUP September 1, 2021 Vivos Inc. 719 Jadwin Avenue Richland, Washington 99352 Re: Offering Statement on Form 1-A for Vivos Inc. Ladies and Gentlemen: We have acted as counsel to Vivos Inc., a Delaware corporation (the “Company”), in connection with the Offering Statement on Form 1-A (the “Offering Statement”) filed
August 2, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: June 30, 2021 OR ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 VIVOS INC (Exact
May 10, 2021	10-Q	Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: March 31, 2021 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 VIVOS INC (
May 7, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2021 VIVOS INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Em
May 7, 2021	EX-10.1	Employment Agreement between Vivos Inc. and Michael Korenko, dated May 3, 2021 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on May 7, 2021. Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this ?Agreement?) is made and entered into as of this 3rd day of May 2021 (the ?Execution Date?), with a deemed effective date of January 1, 2021 (the ?Effective Date?) by and between Vivos Inc.., a company formed under the laws of the State of Delaware, with its principal place of business at Ri
March 24, 2021	10-K	Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-53497 VIVOS INC (Exact name of regi
March 2, 2021	CORRESP	- March 2, 2021 VIA EDGAR Dillon Hagius and Tim Buchmiller Division of Corporate Finance Office of Life Sciences RE: Vivos, Inc.
March 1, 2021	EX1A-6 MAT CTRCT	- Exhibit 6.12 THIS NOTE AND THE SECURITIES INTO WHICH IT IS CONVERTIBLE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR UNLESS THE COMPANY SHALL HAVE RECEIVED AN OPINION OF COUNSE
March 1, 2021	EX1A-11 CONSENT	- Exhibit 11.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the inclusion in this Post-Qualification Offering Circular Amendment No. 3 of our audit report dated April 28, 2020, with respect to the balance sheets of Vivos, Inc. as of December 31, 2019 and December 31, 2018, and the related statements of operations, changes in stockholders? equity, and cash flows for each of
March 1, 2021	EX1A-6 MAT CTRCT	- Exhibit 6.13 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
March 1, 2021	EX1A-12 OPN CNSL	- Exhibit 12.1 OPINION AND CONSENT OF DISCLOSURE LAW GROUP February 17, 2021 Vivos Inc. 719 Jadwin Avenue Richland, Washington 99352 Re: Offering Statement on Form 1-A for Vivos Inc. Ladies and Gentlemen: We have acted as counsel to Vivos Inc., a Delaware corporation (the “Company”), in connection with the Offering Statement on Form 1-A (the “Offering Statement”) filed by the Company with the Securi
March 1, 2021	PART II AND III	- PART II AND III 2 partiiandiii.htm POST-QUALIFICATION OFFERING CIRCULAR DATED MARCH 1, 2021 Vivos Inc. 719 Jadwin Avenue Richland, Washington 99352 (509) 736-4000 http://www.radiogel.com Up to 22,500,000 Shares of Common Stock, par value $0.001 per share at an Offering Price of $0.08 per Share Minimum Investment: 125,000 Shares $10,000 Maximum Offering: 22,500,000 Shares $1,800,000 SEE “DESCRIPTIO
February 17, 2021	EX1A-6 MAT CTRCT	- Exhibit 6.12 THIS NOTE AND THE SECURITIES INTO WHICH IT IS CONVERTIBLE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR UNLESS THE COMPANY SHALL HAVE RECEIVED AN OPINION OF COUNSE
February 17, 2021	PART II AND III	- PART II AND III 2 partiiandiii.htm POST-QUALIFICATION OFFERING CIRCULAR DATED FEBRUARY 17, 2021 Vivos Inc. 719 Jadwin Avenue Richland, Washington 99352 (509) 736-4000 http://www.radiogel.com Up to 22,500,000 Shares of Common Stock, par value $0.001 per share at an Offering Price of $0.08 per Share Minimum Investment: 125,000 Shares $10,000 Maximum Offering: 22,500,000 Shares $1,800,000 SEE “DESCRI
February 17, 2021	EX1A-12 OPN CNSL	- Exhibit 12.1 OPINION AND CONSENT OF DISCLOSURE LAW GROUP February 17, 2021 Vivos Inc. 719 Jadwin Avenue Richland, Washington 99352 Re: Offering Statement on Form 1-A for Vivos Inc. Ladies and Gentlemen: We have acted as counsel to Vivos Inc., a Delaware corporation (the ?Company?), in connection with the Offering Statement on Form 1-A (the ?Offering Statement?) filed by the Company with the Securi
February 17, 2021	EX1A-6 MAT CTRCT	- Exhibit 6.13 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
February 17, 2021	EX1A-11 CONSENT	- Exhibit 11.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the inclusion in this Post-Qualification Offering Circular Amendment No. 2 of our audit report dated April 28, 2020, with respect to the balance sheets of Vivos, Inc. as of December 31, 2019 and December 31, 2018, and the related statements of operations, changes in stockholders? equity, and cash flows for each of
December 23, 2020	S-8	- As filed with the Securities and Exchange Commission on December 23, 2020 Registration No.
December 10, 2020	EX-10.1	Form of Vivos Note 2020 Exhibit 10.1 THIS NOTE AND THE SECURITIES INTO WHICH IT IS CONVERTIBLE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR UNLESS THE COMPANY SHALL HAVE RECEIVED AN OPINION OF COUNSE
December 10, 2020	EX-10.2	Form of Warrant 2020 Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
December 10, 2020	8-K	Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2020 VIVOS INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File Number) (I
November 2, 2020	10-Q	Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: September 30, 2020 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 VIVOS I
August 13, 2020	10-Q/A	Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: March 31, 2020 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 0
August 6, 2020	10-Q	Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: June 30, 2020 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 VIVOS INC (E
June 30, 2020	10-Q	Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: March 31, 2020 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 VIVOS INC (
June 2, 2020	PART II AND III	- POST-QUALIFICATION OFFERING CIRCULAR DATED JUNE 1, 2020 Vivos Inc. 719 Jadwin Avenue Richland, Washington 99352 (509) 736-4000 http://www.radiogel.com Up to 150,000,000 Shares of Common Stock, par value $0.001 per share at an Offering Price of $0.027 per Share Minimum Investment: 370,370 Shares ($10,000) Maximum Offering: 150,000,000 Shares ($4,050,000) SEE “DESCRIPTION OF CAPITAL STOCK” AT PAGE 7
June 2, 2020	EX1A-11 CONSENT	Consent of Independent Registered Public Accounting Firm - Fruci & Associates II, PLLC (filed herewith) Exhibit 11.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the inclusion in this Post-Qualification Offering Circular (Amendment 3) of our audit report dated April 28, 2020, with respect to the balance sheets of Vivos, Inc. as of December 31, 2019 and December 31, 2018, and the related statements of operations, changes in stockholders’ deficit, and cash flows for the years
June 2, 2020	EX1A-12 OPN CNSL	Attorney opinion on legality of the offering (filed herewith) Exhibit 12.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM June 1, 2020 Vivos Inc. 719 Jadwin Avenue Richland, Washington 99352 Re: Offering Statement on Form 1-A for Vivos Inc. Ladies and Gentlemen: We have acted as counsel to Vivos Inc., a Delaware corporation (the “Company”), in connection with the Offering Statement on Form 1-A (the “Offering Statement”) filed by the Company with th
June 1, 2020	CORRESP	- VIVOS INC. Mr. Tim Buchmiller Ms. Mary Beth Breslin Division of Corporation Finance Securities and Exchange Commission Washington DC 20549 June 1, 2020 Re: Vivos Inc. Offering Statement on Form 1-A File No. 024-11049 Dear Ladies and Gentlemen: On behalf of Vivos Inc. I hereby request qualification of the above-referenced offering statement at 10:00 A.M. Eastern time on June 3, 2020, or as soon the
June 1, 2020	CORRESP	- June 1, 2020 VIA EDGAR Mr. Tim Buchmiller and Ms. Mary Beth Breslin United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: VIVOS INC Post-Qualification Amendment No. 2 to Form 1-A Filed May 21, 2020 File No. 024-11049 Ladies and Gentlemen: This letter is submitted on behalf of Vivos Inc. (the “Company”) in response to comments
May 21, 2020	EX1A-11 CONSENT	Consent of Independent Registered Public Accounting Firm - Fruci & Associates II, PLLC (filed herewith) Exhibit 11.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the inclusion in this Post-Qualification Offering Circular (Amendment 2) of our audit report dated April 28, 2020, with respect to the balance sheets of Vivos, Inc. as of December 31, 2019 and December 31, 2018, and the related statements of operations, changes in stockholders’ deficit, and cash flows for the years
May 21, 2020	PART II AND III	- POST-QUALIFICATION OFFERING CIRCULAR DATED MAY 20, 2020 Vivos Inc. 719 Jadwin Avenue Richland, Washington 99352 (509) 736-4000 http://www.radiogel.com Up to 150,000,000 Shares of Common Stock, par value $0.001 per share at an Offering Price of $0.027 per Share Minimum Investment: 370,370 Shares ($10,000) Maximum Offering: 150,000,000 Shares ($4,050,000) SEE “DESCRIPTION OF CAPITAL STOCK” AT PAGE 7
May 21, 2020	EX1A-12 OPN CNSL	Attorney opinion on legality of the offering (filed herewith) Exhibit 12.1 OPINION AND CONSENT OF DISCLOSURE LAW GROUP May 20, 2020 Vivos Inc. 719 Jadwin Avenue Richland, Washington 99352 Re: Offering Statement on Form 1-A for Vivos Inc. Ladies and Gentlemen: We have acted as counsel to Vivos Inc., a Delaware corporation (the “Company”), in connection with the Offering Statement on Form 1-A (the “Offering Statement”) filed by the Company with the Securities
May 20, 2020	8-K/A	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K AMENDMENT NO.
May 20, 2020	10-K/A	Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number:
May 20, 2020	CORRESP	- May 20, 2020 VIA EDGAR Mr. Buchmiller and Ms. Breslin United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: VIVOS INC. Post-Qualification Amendment No. 1 to Form 1-A filed April 30, 2020 File No. 024-11049 Ladies and Gentlemen: This letter is submitted on behalf of Vivos Inc. (the “Company”) in response to comments of the sta
May 20, 2020	8-K/A	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K AMENDMENT NO.
May 8, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2020 VIVOS INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Em
April 30, 2020	EX1A-12 OPN CNSL	Attorney opinion on legality of the offering (filed herewith) Exhibit 12.1 OPINION AND CONSENT OF DISCLOSURE LAW GROUP April 29, 2020 Vivos Inc. 719 Jadwin Avenue Richland, Washington 99352 Re: Offering Statement on Form 1-A for Vivos Inc. Ladies and Gentlemen: We have acted as counsel to Vivos Inc., a Delaware corporation (the “Company”), in connection with the Offering Statement on Form 1-A (the “Offering Statement”) filed by the Company with the Securitie
April 30, 2020	EX1A-11 CONSENT	Consent of Independent Registered Public Accounting Firm - Fruci & Associates II, PLLC (filed herewith) Exhibit 11.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the inclusion in this Post-Qualification Offering Circular of our audit report dated April 28, 2020, with respect to the balance sheets of Vivos, Inc. as of December 31, 2019 and December 31, 2018, and the related statements of operations, changes in stockholders’ deficit, and cash flows for the years then ended, O
April 30, 2020	PART II AND III	- POST-QUALIFICATION OFFERING CIRCULAR DATED APRIL 29, 2020 Vivos Inc. 719 Jadwin Avenue Richland, Washington 99352 (509) 736-4000 http://www.radiogel.com Up to 150,000,000 Shares of Common Stock, par value $0.001 per share at an Offering Price of $0.027 per Share Minimum Investment: 370,370 Shares ($10,000) Maximum Offering: 150,000,000 Shares ($4,050,000) SEE “DESCRIPTION OF CAPITAL STOCK” AT PAGE
April 28, 2020	10-K	Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-53497 VIVOS INC (Exact name of regi
March 16, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2020 VIVOS INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File Number) (IRS
November 22, 2019	CORRESP	RDGL / Vivos Inc CORRESP - - Ms. Amanda Ravitz Mr. Thomas Jones Division of Corporation Finance Securities and Exchange Commission Washington DC 20549 November 22, 2019 Re: Vivos Inc. Offering Statement on Form 1-A File No. 024-11049 Dear Ms. Ravitz and Mr. Jones: On behalf of Vivos Inc. I hereby request qualification of the above-referenced offering statement at 10:00 am Eastern time on November 26, 2019, or as soon thereaft
November 20, 2019	EX1A-12 OPN CNSL	Attorney opinion on legality of the offering (filed herewith) Exhibit 12.1 OPINION AND CONSENT OF DISCLOSURE LAW GROUP November 20, 2019 Vivos Inc. 719 Jadwin Avenue Richland, Washington 99352 Re: Offering Statement on Form 1-A for Vivos Inc. Ladies and Gentlemen: We have acted as counsel to Vivos Inc., a Delaware corporation (the “Company”), in connection with the Offering Statement on Form 1-A (the “Offering Statement”) filed by the Company with the Securi
November 20, 2019	EX1A-4 SUBS AGMT	Subscription Agreement (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form 1-A filed on November 20, 2019). VIVOS INC. SUBSCRIPTION AGREEMENT NOTICE TO INVESTORS THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERI
November 20, 2019	EX1A-11 CONSENT	Consent of Independent Registered Public Accounting Firm - Fruci & Associates II, PLLC (filed herewith) 802 N Washington S Spokane, WA 99201 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the inclusion in this Amended Offering Statement on Form 1-A/A of our audit report dated March 25, 2019 (except for the second paragraph of Note 1, to which the date is September 6, 2019), with respect to the balance sheets of Vivos, Inc.
November 20, 2019	PART II AND III	RDGL / Vivos Inc PART II AND III - - PRELIMINARY OFFERING CIRCULAR DATED NOVEMBER 20, 2019 AN OFFERING STATEMENT PURSUANT TO REGULATION A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
November 14, 2019	10-Q/A	RDGL / Vivos Inc 10-Q/A - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q/A Amendment No. 1 (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: September 30, 2019 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER
November 12, 2019	10-Q	RDGL / Vivos Inc 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: September 30, 2019 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 VIVOS I
October 31, 2019	CORRESP	RDGL / Vivos Inc CORRESP - - October 31, 2019 VIA EDGAR Mr. Gary Newberry Office of Electronics & Machinery Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Vivos Inc. File No. 024-11049 Dear Mr. Newberry: We have received your correspondence dated October 29, 2019 and have addressed your remarks by reproducing below each comment and providing our response immediat
October 8, 2019	EX1A-11 CONSENT	Consent of Independent Registered Public Accounting Firm - Fruci & Associates II, PLLC, filed herewith 802 N Washington S Spokane, WA 99201 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the inclusion in this Amended Offering Statement on Form 1-A/A of our audit report dated March 25, 2019 (except for the second paragraph of Note 1, to which the date is September 6, 2019), with respect to the balance sheets of Vivos, Inc.
October 8, 2019	PART II AND III	RDGL / Vivos Inc PART II AND III - - PRELIMINARY OFFERING CIRCULAR DATED OCTOBER 8, 2019 AN OFFERING STATEMENT PURSUANT TO REGULATION A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
October 8, 2019	EX1A-6 MAT CTRCT	Letter of Amendment to the Amended and Restated Licensing Agreement by and between Battelle Memorial Institute and the Company
October 8, 2019	EX1A-6 MAT CTRCT	Form of Promissory Note, between Advanced Medical Isotope Corporation and AMIC Gift, LLC NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXCHANGEABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATE
October 8, 2019	EX1A-6 MAT CTRCT	Promissory Note Exchange, dated March 28, 2017, between Advanced Medical Isotope Corporation and Carlton M. Cadwell PROMISSORY NOTE SUMMARY OF TERMS March 28, 2017 Value of note: $383,771 Interest rate: 10% Term: Expiration date: December 31, 2017 Note Holder: Carlton M. Cadwell 1361 Gage Blvd Richland, WA 99352 March 28, 2017 Authorized Signature and Title Date 8131 W Grandridge Blvd, #101 · Kennewick, WA 99336 · (509) 736-4000 · (509) 736-4007 fax www.isotopeworld.com
October 8, 2019	EX1A-6 MAT CTRCT	Form of Path Forward and Standstill Agreement PATH FORWARD AND RESTRUCTURING AGREEMENT This Agreement is made as of [] and shall amend that certain Secured Convertible Debenture dated May 9, 2017 (the “Debenture”) in the principal amount of $[] plus the accrued interest thereon by Vivos, Inc (f.
October 8, 2019	EX1A-4 SUBS AGMT	Subscription Agreement VIVOS INC. SUBSCRIPTION AGREEMENT NOTICE TO INVESTORS THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERI
October 8, 2019	CORRESP	RDGL / Vivos Inc CORRESP - - October 8, 2019 VIA EDGAR Mr. Gary Newberry Office of Electronics & Machinery Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Vivos Inc. Amendment to Offering Statement of Form 1-A (“Amendment No. 2”) Filed October 8, 2019 File No. 024-11049 Dear Mr. Newberry: We have received your correspondence dated September 26, 2019 and have addre
September 9, 2019	EX1A-6 MAT CTRCT	Promissory Note Exchange, dated March 28, 2017, between Advanced Medical Isotope Corporation and Carlton M. Cadwell (filed herewith) PROMISSORY NOTE SUMMARY OF TERMS March 28, 2017 Value of note: $383,771 Interest rate: 10% Term: Expiration date: December 31, 2017 Note Holder: Carlton M. Cadwell 1361 Gage Blvd Richland, WA 99352 March 28, 2017 Authorized Signature and Title Date 8131 W Grandridge Blvd, #101 · Kennewick, WA 99336 · (509) 736-4000 · (509) 736-4007 fax www.isotopeworld.com
September 9, 2019	EX1A-6 MAT CTRCT	Form of Promissory Note, between Advanced Medical Isotope Corporation and AMIC Gift, LLC (filed herewith) NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXCHANGEABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATE
September 9, 2019	EX1A-11 CONSENT	Consent of Independent Registered Public Accounting Firm - Fruci & Associates II, PLLC, filed herewith 802 N Washington S Spokane, WA 99201 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the inclusion in this Amended Offering Statement on Form 1-A/A of our audit report dated March 25, 2019 (except for the second paragraph of Note 1, to which the date is September 6, 2019), with respect to the balance sheets of Vivos, Inc.
September 9, 2019	EX1A-6 MAT CTRCT	Letter of Amendment to the Amended and Restated Licensing Agreement by and between Battelle Memorial Institute and the Company (filed herewith)
September 9, 2019	EX1A-6 MAT CTRCT	Form of Path Forward and Standstill Agreement (filed herewith) PATH FORWARD AND RESTRUCTURING AGREEMENT This Agreement is made as of [] and shall amend that certain Secured Convertible Debenture dated May 9, 2017 (the “Debenture”) in the principal amount of $[] plus the accrued interest thereon by Vivos, Inc (f.
September 9, 2019	PART II AND III	RDGL / Vivos Inc PART II AND III - - PRELIMINARY OFFERING CIRCULAR DATED SEPTEMBER 9, 2019 AN OFFERING STATEMENT PURSUANT TO REGULATION A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
September 9, 2019	CORRESP	RDGL / Vivos Inc CORRESP - - September 9, 2019 VIA EDGAR Mr. Gary Newberry Office of Electronics & Machinery Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Vivos Inc. Offering Statement of Form 1-A Filed July 29, 2019 File No. 024-11049 Dear Mr. Newberry: We have received your correspondence dated August 23, 2019. We have addressed your comment by reproducing bel
August 13, 2019	10-Q	RDGL / Vivos Inc 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: June 30, 2019 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 VIVOS INC (E
July 29, 2019	EX1A-6 MAT CTRCT	Employment Agreement by and between Vivos Inc. and Michael Korenko, dated June 4, 2019 (incorporated by reference to Exhibit 6.18 to the Company’s Offering Statement on Form 1-A filed on July 29, 2019).
July 29, 2019	EX1A-11 CONSENT	Consent of Independent Registered Public Accounting Firm - Fruci & Associates II, PLLC, filed herewith CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the inclusion in this Offering Statement on Form 1-A of our audit report dated March 25, 2019, with respect to the balance sheets of Vivos, Inc.
July 29, 2019	PART II AND III	RDGL / Vivos Inc PART II AND III - - PRELIMINARY OFFERING CIRCULAR DATED JULY 29, 2019 AN OFFERING STATEMENT PURSUANT TO REGULATION A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
July 2, 2019	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 26, 2019 Vivos Inc. (Exact name of registrant as specified in its charter) Delaware 00-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File Number) (I
July 2, 2019	EX-99.2	Vivos Inc. Issues Corrective Press Release Regarding Reverse Stock Split Vivos Inc. Issues Corrective Press Release Regarding Reverse Stock Split Richland, WA, June 27, 2019. Vivos Inc. (the “Company”) (OTC PINK: RDGL), a company engaged in the development and commercialization of minimally invasive brachytherapy treatments to combat cancer in animals and humans, is issuing this press release to correct its press release dated June 26, 2019, which announced that it wou
July 2, 2019	EX-99.1	Vivos Inc. Vivos Inc. Announces 1-for-8 Reverse Stock Split Vivos Inc. Vivos Inc. Announces 1-for-8 Reverse Stock Split Richland, WA, June 26, 2019 (GLOBAL NEWSWIRE) – Vivos Inc. (OTC PINK: RDGL) Vivos Inc. (the “Company”) (OTC PINK: RDGL), a company engaged in the development and commercialization of minimally invasive brachytherapy treatments to combat cancer in animals and humans, today announced that it will effect a 1-for-8 reverse stock split of its
July 2, 2019	EX-3.1	Certificate of Amendment to the Certificate of Incorporation decreasing the number of shares of common stock authorized for issuance to 950,000,000 and effecting a 1-for-8 reverse stock split of the Company’s issued and outstanding common stock, filed June 26, 2019 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on July 2, 2019). CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF VIVOS INC Pursuant to Section 242 of the General Corporation Law of the State of Delaware, the undersigned, by and on behalf of Vivos Inc (the “Corporation”), a corporation duly organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY: FIRST: This Certificate of Amendment amends the provisions of the Corporation’s Certificate of Incorporation, as amended (the “Certificate of Incorporation”).
June 24, 2019	10-Q/A	RDGL / Vivos Inc 10-Q/A - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q/A Amendment No. 1 (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: March 31, 2019 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000
May 22, 2019	DEFR14C	RDGL / Vivos Inc DEFR14C - - DEFR14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [ ] Preliminary Information Statement [X] Definitive Information Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) Vivos Inc. (Name of Registrant as Specified
May 16, 2019	DEF 14C	RDGL / Vivos Inc DEF 14C DEF 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [ ] Preliminary Information Statement [X] Definitive Information Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) Vivos Inc. (Name of Registrant as Specified
May 13, 2019	10-Q	RDGL / Vivos Inc 10-Q Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: March 31, 2019 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 VIVOS INC (
April 26, 2019	PRE 14C	RDGL / Vivos Inc PRE 14C PRE 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Definitive Information Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) Vivos Inc. (Name of Registrant as Specified
April 2, 2019	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 27, 2019 Commission File Number: 0001449349 Vivos Inc.
April 2, 2019	EX-3	Certificate of Amendment to the Certificate of Incorporation authorizing a series of Preferred Stock to be named “Series C Convertible Preferred Stock”, consisting of 5,000,000 shares, which series shall have specific designations, powers, preferences and relative and other special rights, qualifications, limitations and restrictions as outlined in the Certificate of Designations, filed March 27, 2019 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on April 2, 2019). Exhibit 3.1 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES C CONVERTIBLE PREFERRED STOCK OF VIVOS, INC. The undersigned, the Chief Executive Officer of Vivos, Inc., a Delaware corporation (the “Company”), does hereby certify that, pursuant to the authority conferred upon the Board of Directors by the Certificate of Incorporation of the Company, the following resolution creating a se
March 25, 2019	10-K	RDGL / Vivos Inc (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-53497 VIVOS INC (Exact name of regi
January 31, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 25, 2019 Commission File Number: 0001449349 Vivos Inc.
December 11, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2018 Vivos Inc. (Exact name of registrant as specified in its charter) Delaware 000-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File Number
December 6, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 26, 2018 Commission File Number: 0001449349 Vivos Inc.
November 14, 2018	10-Q	RDGL / Vivos Inc 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: September 30, 2018 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 VIVOS I
October 30, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 24, 2018 Vivos Inc. (Exact name of registrant as specified in its charter) Delaware 00-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File Number)
October 30, 2018	EX-10.2	Employment Agreement by and between Vivos Inc. and Leonard Bruce Jolliff, dated October 24, 2018 (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on October 30, 2018). EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT, entered into the 24th day of October, 2018, between Vivos Inc Board of Directors (herein called the “Company”), and Leonard B.
October 30, 2018	EX-10.1	Employment Agreement by and between Vivos Inc. and Michael Korenko, dated October 24, 2018 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on October 30, 2018). EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT, entered into the 24th day of October, 2018, between Vivos, Inc.
October 17, 2018	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 10, 2018 Vivos Inc. (Exact name of registrant as specified in its charter) Delaware 00-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File Number)
October 17, 2018	EX-10.1	Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on October 17, 2018). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October , 2018, between Vivos, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth
October 17, 2018	EX-4.1	Form of Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on October 17, 2018). Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
October 17, 2018	EX-3.1	Certificate of Amendment to the Certificate of Incorporation authorizing a series of Preferred Stock to be named “Series B Convertible Preferred Stock”, consisting of 5,000,000 shares, which series shall have specific designations, powers, preferences and relative and other special rights, qualifications, limitations and restrictions as outlined in the Certificate of Designations, filed October 10, 2018 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on October 17, 2018). Exhibit 3.1 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES B CONVERTIBLE PREFERRED STOCK OF VIVOS, INC. The undersigned, the Chief Executive Officer of Vivos, Inc., a Delaware corporation (the “Company”), does hereby certify that, pursuant to the authority conferred upon the Board of Directors by the Certificate of Incorporation of the Company, the following resolution creating a se
October 5, 2018	RW	RDGL / Vivos Inc REQUEST FOR WITHDRAWAL VIVOS INC. 719 Jadwin Avenue Richland, Washington 99352 October 5, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re : Vivos Inc Request for Withdrawal of Registration Statement on Form S-1 and Pre-Effective Amendment No. 1 on Form S-1/A filed on March 10, 2017 and February 9, 2018, respectively (File No. 33
September 25, 2018	EX-99.1	Vivos Inc Signs a Standstill Agreement with Debt Holders Designed to Halt the Toxic Selling and Eliminate the Secured Toxic Debt Exhibit 99.1 Vivos Inc Signs a Standstill Agreement with Debt Holders Designed to Halt the Toxic Selling and Eliminate the Secured Toxic Debt (Richland WA – September 24, 2018) - Vivos, Inc. (OTC PINK: RDGL) Vivos Inc is pleased to announce that all the debtholders of Vivos’ secured convertible debt have agreed to a ten trading day market standstill, during which time they agree to refrain from an
September 25, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 24, 2018 Vivos Inc. (Exact name of registrant as specified in its charter) Delaware 00-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File Numbe
September 21, 2018	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 21, 2018 Vivos Inc. (Exact name of registrant as specified in its charter) Delaware 00-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File Numbe
August 20, 2018	10-Q	RDGL / Vivos Inc 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: June 30, 2018 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 VIVOS INC (E
August 14, 2018	NT 10-Q	RDGL / Vivos Inc NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 000-1449349 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: June 30, 2018 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transi
May 22, 2018	10-Q	RDGL / Vivos Inc QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: March 31, 2018 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 VIVOS INC (
May 15, 2018	NT 10-Q	RDGL / Vivos Inc NT 10-Q OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response .
April 2, 2018	EX-10.14	The Curators of the University of Missouri Sponsored Research Contract for the period November 1, 2017 through October 31, 2018. (incorporated by reference to Exhibit 10.14 to the Company’s Annual report on Form 10-K, filed April 2, 2018).
April 2, 2018	EX-10.13	Washington State University Sub-Award Agreement for the period December 15, 2017 through January 31, 2018.(incorporated by reference to Exhibit 10.13 to the Company’s Annual report on Form 10-K, filed April 2, 2018).
April 2, 2018	10-K	RDGL / Vivos Inc 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-53497 VIVOS INC (Exact name of regi
February 16, 2018	EX-24	FORM 5 [X] Check box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). [ ] Form 3 Holdings Reported. [X] Form 4 Transactions Reported. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C Untitled Document FORM 5 [X] Check box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). [ ] Form 3 Holdings Reported. [X] Form 4 Transactions Reported. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 o
February 9, 2018	S-1/A	As filed with the Securities and Exchange Commission on February 8 , 2018 As filed with the Securities and Exchange Commission on February 8 , 2018 Registration No.
February 8, 2018	CORRESP	RDGL / Vivos Inc CORRESP February 8, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
January 25, 2018	10-K/A	RDGL / Vivos Inc 10-K/A (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-53497 VIVOS INC. (Exact name of r
January 25, 2018	EX-10.13	Amended and Restated License Agreement by and between Battelle Memorial Institute and Advanced Medical Isotope Corporation (incorporated by reference to Exhibit 10.13 to Amendment No. 1 to the Company’s Annual Report on Form 10-K, filed on January 25, 2018). AMENDED AND RESTATED LICENSE AGREEMENT NO. 525855 BETWEEN BATTELLE MEMORIAL INSTITUTE AND ADVANCED MEDICAL ISOTOPE CORPORATION March 2017 BUSINESS SENSITIVE License Agreement No. 525855 – Amended and Restated (Amendment 1) Advanced Medical Isotope Corporation March 14, 2017 Version 1 LICENSE AGREEMENT 525855 AMENDED AND RESTATED THIS AGREEMENT made and entered into at Richland, Washington, as the
January 24, 2018	CORRESP	RDGL / Vivos Inc CORRESP January 24, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
January 10, 2018	S-8	ADMD / Advanced Medical Isotope Corp. As filed with the Securities and Exchange Commission on January 10, 2018 Registration No.
January 9, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Vivos Inc. - FORM 8-k UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 31, 2017 Commission File Number: 0001449349 Vivos Inc. (Exact name of registrant as specified in its charter.) Delaware (State or other jurisdiction of in
January 2, 2018	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 28, 2017 Vivos Inc. (Exact name of registrant as specified in its charter) Delaware 00-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File Number
January 2, 2018	EX-1	STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION ex1-01022018010107.htm STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION The undersigned, by and on behalf of Advanced Medical Isotope Corporation (the ?Corporation?), a corporation duly organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: FIRST: by unanimous written consent of the Board of Directors of th
January 2, 2018	EX-99	Advanced Medical Isotope Corporation (ADMD) Announces Corporate Name Change to Vivos Inc., and Ticker Symbol Change to RDGL Secconnect.com Advanced Medical Isotope Corporation (ADMD) Announces Corporate Name Change to Vivos Inc., and Ticker Symbol Change to RDGL Richland, WA, January 2, 2018. Advanced Medical Isotope Corporation (OTCPink: RDGL) announced today that it has changed its name to Vivos Inc., and that its shares are scheduled to trade under the new symbol, RDGL, on the OTC Markets on January 2, 2018. Both of
December 18, 2017	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2017 ADVANCED MEDICAL ISOTOPE CORPORATION (Exact name of Registrant as specified in its Charter) Delaware 00-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File No.
December 18, 2017	EX-10	Form of Agreement to Amend Senior Secured Convertible Debentures (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on December 18, 2017). ex10-12182017021223.htm Exhibit 10.1 AGREEMENT TO AMEND SENIOR SECURED CONVERTIBLE DEBENTURE MATURING MAY 9, 2018 IN THE ORIGINAL PRINCIPAL AMOUNT OF $[] This Agreement is made as of December 13, 2017, and shall amend that certain Secured Convertible Debenture dated May [], 2017 in the principal amount of $[] issued by Advanced Medical Isotope Corporation, a Delaware corporation (the Company?) to
November 13, 2017	10-Q	RDGL / Vivos Inc 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: September 30, 2017 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 ADVANCE
September 14, 2017	EX-10.2	Form of Employment Agreement dated September 1, 2017 with Leonard B. Jolliff (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed on September 15, 2017). EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT, entered into the 1st day of September, 2017, between the Advanced Medical Isotope Corporation Board of Directors (herein called the ?Company?), and Leonard B.
September 14, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2017 ADVANCED MEDICAL ISOTOPE CORPORATION (Exact name of Registrant as specified in its Charter) Delaware 00-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File No.
September 14, 2017	EX-10.1	Form of Employment Agreement dated September 1, 2017 with Dr. Michael K. Korenko (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on September 15, 2017). EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT, entered into the 1st day of September, 2017, between the Advanced Medical Isotope Corporation Board of Directors (herein called the ?Company?), and Dr.
August 11, 2017	EX-10.4	Form of $0.12 Debenture (incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q, filed on August 11, 2017). NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.
August 11, 2017	EX-10.1	Form of Securities Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q, filed on August 11, 2017). SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of May , 2017 (this “Agreement”), is among Advanced Medical Isotope Corporation, a Delaware corporation (the “Debtor”) and each holder of the Debtor’s 7.
August 11, 2017	EX-10.2	Form of $0.20 Debenture (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q, filed on August 11, 2017). NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.
August 11, 2017	10-Q	RDGL / Vivos Inc 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: June 30, 2017 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 ADVANCED MED
August 11, 2017	EX-10.3	Form of $0.13 Debenture (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q, filed on August 11, 2017). NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.
August 11, 2017	EX-10.6	Form of Security Purchase Agreement (incorporated by reference to Exhibit 10.6 to the Company’s Quarterly Report on Form 10-Q, filed on August 11, 2017). SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , between Advanced Medical Isotope Corporation, a Delaware corporation (the “Company”), and the purchaser identified on the signature pages hereto (including its successors and assigns, the “Purchaser”).
August 11, 2017	EX-10.5	Form of Securities Exchange Agreement (incorporated by reference to Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q, filed on August 11, 2017). SECURITIES EXCHANGE AGREEMENT This Securities Exchange Agreement (this “Agreement”) is dated as of May , 2017, between Advanced Medical Isotope Corporation, a Delaware corporation (the “Company”), and (“Holder”).
August 4, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2017 ADVANCED MEDICAL ISOTOPE CORPORATION (Exact name of Registrant as specified in its Charter) Delaware 00-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File No.
August 1, 2017	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2017 ADVANCED MEDICAL ISOTOPE CORPORATION (Exact name of Registrant as specified in its Charter) Delaware 00-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File No.
August 1, 2017	EX-99.1	EX-99.1
July 10, 2017	DEF 14A	Advanced Medical Isotope 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the SEC Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive Proxy St
June 28, 2017	PRE 14A	Advanced Medical Isotope 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the SEC Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Proxy St
May 15, 2017	EX-10.2	Form of $0.20 Debenture (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q, filed on May 15, 2017). NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.
May 15, 2017	EX-10.5	Form of Security Agreement (incorporated by reference to Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q, filed on May 15, 2017). SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of May , 2017 (this ?Agreement?), is among Advanced Medical Isotope Corporation, a Delaware corporation (the ?Debtor?) and each holder of the Debtor?s 7.
May 15, 2017	EX-10.6	Form of Security Purchase Agreement (incorporated by reference to Exhibit 10.6 to the Company’s Quarterly Report on Form 10-Q, filed on May 15, 2017). SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of , between Advanced Medical Isotope Corporation, a Delaware corporation (the ?Company?), and the purchaser identified on the signature pages hereto (including its successors and assigns, the ?Purchaser?).
May 15, 2017	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: March 31, 2017 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 ADVANCED ME
May 15, 2017	EX-10.3	Form of $0.13 Debenture (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q, filed on May 15, 2017). NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.
May 15, 2017	EX-10.1	Form of Securities Exchange Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q, filed on May 15, 2017). SECURITIES EXCHANGE AGREEMENT This Securities Exchange Agreement (this “Agreement”) is dated as of May , 2017, between Advanced Medical Isotope Corporation, a Delaware corporation (the “Company”), and (“Holder”).
May 15, 2017	EX-10.4	Form of $0.12 Debenture (incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q, filed on May 15, 2017). NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.
March 10, 2017	S-1	Power of Attorney (included on the signature page of the Registration Statement filed on March 10, 2017 ). As filed with the Securities and Exchange Commission on March 9, 2017 Registration No.
March 9, 2017	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-53497 ADVANCED MEDICAL ISOTOPE CORP
December 20, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2016 ADVANCED MEDICAL ISOTOPE CORPORATION (Exact name of Registrant as specified in its Charter) Delaware 00-53497 80-0138937 (State or other jurisdiction of incorporation) (Commission File No.
December 20, 2016	EX-99	Board of Directors Appoints Dr. Michael Korenko CEO, Dr. Carlton Cadwell Chairman of Advanced Medical Isotope Corporation Secconnect.com Board of Directors Appoints Dr. Michael Korenko CEO, Dr. Carlton Cadwell Chairman of Advanced Medical Isotope Corporation Kennewick, WA / Accesswire / December 20, 2016 / Advanced Medical Isotope Corporation (?AMI?) (OTC: ADMD), a late stage radiation oncology focused medical device company, announced that Dr. Michael Korenko, Ph. D., who formerly served as an advisor to the Board,
November 21, 2016	EX-10.2	Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q, filed November 21, 2016). Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of November , 2016, by and between ADVANCED MEDICAL ISOTOPE CORP., a Delaware corporation, with headquarters located at 1021 N. Kellogg Street, Kennewick, WA 99336 (the “Company”), and , a , with its address (the “Buyer”). WHEREAS: A. The Company and the Buyer are executing and delivering this
November 21, 2016	EX-10.1	Form of Convertible Promissory Note (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q, filed November 21, 2016). Exhibit 10.1 NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR
November 21, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: September 30, 2016 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 ADVANCE
November 15, 2016	NT 10-Q	Advanced Medical Isotope 0-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR [ ] Form N-CSR For Period Ended: September 30, 2016 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
October 17, 2016	EX-3.1	Certificate of Amendment to the Certificate of Incorporation of Advanced Medical Isotope Corporation, effective October 7, 2016 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on October 17, 2016). STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION Advanced Medical Isotope Corporation, organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: FIRST: That the Board of Directors of Advanced Medical Isotope Corporation adopted a proposed amendment of the Certificate of Incorporation of said corporation to effectuate a reverse stock split, declaring said amendment to be advisable.
October 17, 2016	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2016 ADVANCED MEDICAL ISOTOPE CORP.
September 1, 2016	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2016 Advanced Medical Isotope Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 0-53497 80-0138937 (State of Incorporation) (Commission File No.
August 24, 2016	EX-16.1	EX-16.1
August 24, 2016	EX-16.1	EX-16.1
August 24, 2016	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2016 Advanced Medical Isotope Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 0-53497 80-0138937 (State of Incorporation) (Commission File No.)
August 24, 2016	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2016 Advanced Medical Isotope Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 0-53497 80-0138937 (State of Incorporation) (Commission File No.)
August 18, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: June 30, 2016 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 ADVANCED MED
August 15, 2016	NT 10-Q	Advanced Medical Isotope 0-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR [ ] Form N-CSR For Period Ended: June 30, 2016 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
August 15, 2016	NT 10-Q	Advanced Medical Isotope 0-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR [ ] Form N-CSR For Period Ended: June 30, 2016 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
June 30, 2016	SC 13G	ADMD / Advanced Medical Isotope Corp. / UNION CAPITAL, LLC - SCHEDULE 13G Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Advanced Medical Isotope Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 00765X102 (CUSIP Number) June 8, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch
June 10, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: March 31, 2016 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53497 ADVANCED ME
May 26, 2016	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-53497 ADVANCED
May 26, 2016	EX-10.12	ADVANCED MEDICAL ISOTOPE CORPORATION 2015 OMNIBUS SECURITIES AND INCENTIVE PLAN ADVANCED MEDICAL ISOTOPE CORPORATION 2015 OMNIBUS SECURITIES AND INCENTIVE PLAN Table of Contents ADVANCED MEDICAL ISOTOPE CORPORATION 2015 OMNIBUS SECURITIES AND INCENTIVE PLAN ADVANCED MEDICAL ISOTOPE CORPORATION 2015 OMNIBUS SECURITIES AND INCENTIVE PLAN Table of Contents Page ARTICLE I PURPOSE 1 ARTICLE II DEFINITIONS 1 ARTICLE III EFFECTIVE DATE OF PLAN 7 ARTICLE IV ADMINISTRATION 7 Section 4.
May 25, 2016	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-53497 ADVANCED MEDICAL ISOTOPE CORP
May 25, 2016	EX-10.12	2015 Omnibus Securities and Incentive Plan (incorporated by reference to Exhibit 10.12 to the Company’s Annual Report on Form 10-K, filed May 25, 2016). ADVANCED MEDICAL ISOTOPE CORPORATION 2015 OMNIBUS SECURITIES AND INCENTIVE PLAN ADVANCED MEDICAL ISOTOPE CORPORATION 2015 OMNIBUS SECURITIES AND INCENTIVE PLAN Table of Contents Page ARTICLE I PURPOSE 1 ARTICLE II DEFINITIONS 1 ARTICLE III EFFECTIVE DATE OF PLAN 7 ARTICLE IV ADMINISTRATION 7 Section 4.
May 17, 2016	NT 10-Q	Advanced Medical Isotope 0-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR [ ] Form N-CSR For Period Ended: March 31, 2016 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
April 6, 2016	EX-10.01	Certificate of Amendment to the Certificate of Incorporation increasing the authorized series of “Series A Convertible Preferred Stock” to 5,000,000 shares, filed March 31, 2016 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 7, 2016).
April 6, 2016	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2016 Advanced Medical Isotope Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 0-53497 80-0138937 (State of Incorporation) (Commission File No.) (
March 30, 2016	NT 10-K	Advanced Medical Isotope ADVANCED MEDICAL ISOTOPE CORP. 12/31/2015 NT 10-K admdnt10k-16807.htm OMB APPROVAL UNITED STATES OMB Number: . . . . . 3235-0058 SECURITIES AND EXCHANGE COMMISSION Estimated average burden Washington, D.C. 20549 hours per response. . . . . . 2.5 SEC FILE NUMBER FORM 12b-25 0-53497 CUSIP NUMBER NOTIFICATION OF LATE FILING 00765X102 (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended:
January 19, 2016	EX-16.1	Letter from HJ & Associates, LLC dated January 19, 2016 exhibit16-1.htm Exhibit 16.1 January 19, 2016 U.S. Securities and Exchange Commission 100 F. Street Washington, DC 20549 ? 7561 Ladies and Gentlemen: We have read the statements of Advanced Medical Isotope Corporation pertaining to our firm included in Item 4.01 of the Form 8-K dated January 19, 2016 and are in agreement with the statements contained in that document pertaining to our firm. Sincer
January 19, 2016	8-K	Current Report advancedmed8k-16716.htm SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2016 ADVANCED MEDICAL ISOTOPE CORP. (Exact name of Registrant as specified in its Charter) Delaware 00-53497 80-0138937 (State or other jurisdiction of incorporati
January 15, 2016	SC 13G/A	RDGL / Vivos Inc / Typenex Co-Investment, LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* Advanced Medical Isotope Corp (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 00765x102 (CUSIP Number) Calendar Year 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de
December 14, 2015	DEF 14C	Advanced Medical Isotope 14C admddef14cnov2015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [ ] Preliminary Information Statement [X] Definitive Information Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) Advanced Medical Isoto
November 25, 2015	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-5349
November 24, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53497 ADVANCED MEDICAL I
November 16, 2015	NT 10-Q	Advanced Medical Isotope 0-Q Advanced Medical Isotope Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response .
October 30, 2015	PRE 14C	Advanced Medical Isotope 14C admdpre14coct2015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Definitive Information Statement [ ] Confidential for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) Advanced Medical Isoto
September 16, 2015	EX-10	Form of Exchange Agreement by and between the Company and Carlton Cadwell (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on September 16, 2015). EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (this ?Agreement?) is dated as of September , 2015 (the ?Closing Date?), between Advanced Medical Isotope Corporation, a Delaware corporation (the ?Company?) and (the ?Holder?).
September 16, 2015	EX-10	Form of Promissory Note, by and between the Company and Carlton Cadwell (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed on September 16, 2015). ex10-09152015050940.htm PROMISSORY DEMAND NOTE $ September , 2015 FOR VALUE RECEIVED, Advanced Medical Isotope Corporation, (the ?Borrower?), hereby promises to pay to the order of , (the ?Lender?), the principal sum of $ plus interest, payable at maturity, at the rate of eight percent (8%), as set forth below. Principal and accrued interest shall be due and payable on demand, with thirty (30) day
September 16, 2015	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events Advanced Medical Isotope Corporation - FORM 8-k UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 10, 2015 Commission File Number: 0001449349 Advanced Medical Isotope Corporation (Exact name of small business issuer as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 80-0138937 (IRS Employer Identification No.
August 19, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53497 ADVANCED MEDICAL ISOTOP
August 14, 2015	NT 10-Q	Advanced Medical Isotope 0-Q Advanced Medical Isotope Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response .
July 8, 2015	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits admd8k-16465.htm SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2015 ADVANCED MEDICAL ISOTOPE CORP. (Exact name of Registrant as specified in its Charter) Delaware 00-53497 80-0138937 (State or other jurisdiction of incorporation) (Commi
July 8, 2015	EX-4.1	Certificate of Amendment to the Certificate of Incorporation authorizing a series of Preferred Stock to be named “Series A Convertible Preferred Stock”, consisting of 2,500,000 shares, which series shall have specific designations, powers, preferences and relative and other special rights, qualifications, limitations and restrictions as outlined in the Certificate of Designations, filed June 30, 2015 (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on July 7, 2015). exhibit4-1.htm EXHIBIT 4.1 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES A CONVERTIBLE PREFERRED STOCK OF ADVANCED MEDICAL ISOTOPE CORPORATION The undersigned, the Chief Executive Officer of Advanced Medical Isotope Corporation, a Delaware corporation (the ?Company?), does hereby certify that, pursuant to the authority conferred upon the Board of Directors by the Certificate of Inc
July 1, 2015	EX-99.1	Advanced Medical Isotope Corporation Provides Commercialization and Strategic Plan Update exhibit99-1.htm EXHIBIT 99.1 Advanced Medical Isotope Corporation Provides Commercialization and Strategic Plan Update KENNEWICK, WA / Investors Hub / June 24, 2015 / Advanced Medical Isotope Corporation ("AMIC") (ADMD), a late stage development company engaged in the development of brachytherapy devices for therapeutic applications, today provided an update on the Y-90 RadioGel(TM) device de novo
July 1, 2015	8-K	Financial Statements and Exhibits, Other Events admd8k-16461.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2015 ADVANCED MEDICAL ISOTOPE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-53497 80-0138937 (State or other jurisdiction o
May 27, 2015	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q /A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q /A Amendment No. 1 (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: March 31, 2015 OR o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 000-53

RDGL / Vivos Inc. - Документы SEC, Годовой отчет, Доверенное заявление

Основная статистика

SEC Filings

SEC Filings (Chronological Order)